By Tech Guru : Actinium ( OTCQB:ATNM ) has received some more interest since my last article on October 15th, and has continued to put out impressive data, which combined with the recent offer by Bayer ( OTCPK:BAYZF ) for $2.4 billion on Algeta ASA ( OTCPK:ALGZF ), the other alpha emitter cancer ...
for Medicare and Medicaid Services for its accountable care pilot program. The emergence of competing biosimilar products for Amgen 's Epogen could eventually improve DaVita's profitability. Management has historically followed prudent capital allocation
our previous estimate. We’ve also boosted our probability of approval for Actavis’ biosimilars under development with Amgen following recent industry advancements of these products into clinical trials with the FDA. Although Actavis' U.S. generic
forms of manipulation because the stereotypical investor buying these risky companies is often on the hunt for the next Amgen ( AMGN ) with its spicy 100,000% return on investment (ROI). While a 100,000% ROI is a nice goal, it's not very
later and is selling better than Amgen 's ( AMGN ) Kyprolis. Pomalyst, approved ..... quarter. Kyprolis was acquired by Amgen as part of the $10.4 billion purchase of Onyx Pharmaceuticals, which Amgen closed on October 1. The two drugs
By Premier Penny Stocks : It is estimated that in 2013 there will be approximately 77,000 new cases of melanoma in the U.S. resulting in almost 10,000 deaths. In 2009 the University of California created a model comparing the estimated costs of melanoma at various clinical stages. The ...
Goldman is out with an update on IMS data for some of Amgen 's ( AMGN ) key drugs. "Sales are tracking slightly ahead of ..... sales coming in at $76M versus consensus of $71M. AMGN reiterated at Buy. Price target is $130. Post your
MannKind ( MNKD ) at Neutral. Nektar Therapeutics ( NKTR ) is initiated at Overweight at Piper. Price target is $20. Amgen ( AMGN ) initiated at Overweight at Piper. Price target is $143. Vanda ( VNDA ) started at Overweight at Piper. Price target
NEW YORK, Nov 22 (Reuters) - Two traders have won the dismissal of a U.S. Securities and Exchange Commission lawsuit accusing them of insider trading in Onyx Pharmaceuticals Inc as the company considered a takeover bid from rival Amgen Inc .
By Abba's Aces: The last time I wrote about Amgen ( AMGN ) I bought a small batch in it stating that was a good ..... versus the 8.46% gain the S&P500 ( SPY ) posted. Amgen is a global biotech company (the first of its kind